Financial Data and Key Metrics Changes - In Q1, the company reported revenue of $879 million, representing a decline of 7.7% year-over-year, with organic sales down 4.4% due to a negative 4% BiTE impact [23][24] - Adjusted EPS for the quarter was $0.43, up 3.7% from the prior year, driven by higher adjusted EBITDA margins and a lower share count [25] - Adjusted EBITDA margins expanded by 220 basis points, benefiting from lower operating expenses and transformational savings [25] Business Line Data and Key Metrics Changes - Essential Dental Solutions segment saw organic sales increase by 0.4%, driven by growth in Europe and the rest of the world, despite lower volumes in the U.S. [27] - Orthodontic and Implant Solutions segment experienced a significant organic sales decline of 17.7%, primarily due to the loss of a DSO customer in the U.S. and lower lab volumes globally [28] - Connected Technology Solutions segment reported a slight organic sales decline of 0.5%, largely due to CADCAM declines in the U.S., although imaging performance showed growth across all regions [29] Market Data and Key Metrics Changes - U.S. organic sales declined by 14.9%, primarily impacted by a negative 9.8% from BiTE, while imaging growth was noted [31] - Europe saw organic sales increase by 1.1%, driven by strong performance in Germany, particularly in equipment and instruments [34] - Rest of World organic sales grew by 3.1%, with growth in imaging and WellSpec in China, offset by CADCAM declines [35] Company Strategy and Development Direction - The company is focused on driving reliable and sustainable performance, emphasizing customer-centric product innovation and operational efficiency [8][10] - The strategy includes enhancing the digital ecosystem through the DS Core platform, which has gained traction with over 42,000 unique users [14] - The company aims to improve customer engagement through revamped websites and a new e-commerce platform [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating global trade challenges and has developed plans to mitigate potential impacts from tariffs [7][12] - Despite a challenging macroeconomic environment, the company maintained its outlook for organic sales and adjusted EPS for 2025, while increasing reported sales expectations due to foreign currency translation changes [12][36] - Management noted stable patient volume and procedure utilization, although U.S. dentists expressed concerns about economic conditions affecting patient footfall [11] Other Important Information - The company is actively managing its balance sheet and has taken actions to strengthen its position, including entering into a bridge loan agreement [26] - The company has completed the closure of 10 manufacturing and distribution sites as part of its supply chain optimization efforts [23] Q&A Session Summary Question: Can you expand on the tariff impact? - Management indicated that tariffs have been factored into guidance, estimating an annualized impact of approximately $50 million, with about $0.10 impact on EPS [49][50] Question: Update on CFO search? - Management reported good progress in the CFO search, with candidates in the late phases of the process [52] Question: Insights on orthodontics and SureSmile? - Management acknowledged the need to reengage with the orthodontist community and improve user experience for SureSmile [58] Question: Clarification on EBIT margin? - Management noted that Q1 EBIT margin improvements are indicative of future performance, with a focus on judicious SG&A management [62] Question: Cash flow and CapEx expectations? - Management expects CapEx to decrease as ERP projects roll off, leading to improved free cash flow [108]

DENTSPLY SIRONA (XRAY) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Please be advised that today's conference is being recorded. I would now like to hand the call over to Andrea Daley, Vice President of Investor Relations. Please go ahead. Speaker1 Thank you, operator, and good morning, everyone. Welcome to the Dentsply Thirona first quarter twenty twenty five earnings call. Joining me for today's call is Simon Campion, Chief Executive Officer and Rich Rosenzweig, Executive Vice President, Corpor ...

Company Performance - Dentsply International reported quarterly earnings of $0.43 per share, exceeding the Zacks Consensus Estimate of $0.29 per share, and showing a slight increase from $0.42 per share a year ago, resulting in an earnings surprise of 48.28% [1] - The company posted revenues of $879 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.22%, although this represents a decline from year-ago revenues of $953 million [2] - Over the last four quarters, Dentsply has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Outlook - Dentsply shares have declined approximately 27.9% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.45 on revenues of $911.58 million, and for the current fiscal year, it is $1.79 on revenues of $3.56 billion [7] - The estimate revisions trend for Dentsply is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Dental Supplies industry, to which Dentsply belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% of industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

First Quarter 2025 Earnings Conference Call May 8, 2025 Forward-Looking Statements and Associated Risks All statements in this Presentation that do not directly and exclusively relate to historical facts constitute "forward-looking statements." Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control, including those described in Part I, It ...

Net sales of $879 million decreased (7.7%), organic sales decreased (4.4%) including a (4.0%) Byte sales impactGAAP gross margin of 53.0%, GAAP net income of $20 million or $0.10 per shareAdjusted gross margin of 56.3%, adjusted EBITDA margin of 19.0%, adjusted EPS of $0.43Maintaining FY25 outlook for organic sales and adjusted EPS; increasing reported sales due to F/X changes CHARLOTTE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today ann ...

Company Performance - Staar Surgical reported a quarterly loss of $0.52 per share, which was better than the Zacks Consensus Estimate of a loss of $0.59, and compared to earnings of $0.06 per share a year ago, indicating an earnings surprise of 11.86% [1] - The company posted revenues of $42.59 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.57%, but down from $77.36 million in the same quarter last year [2] - Over the last four quarters, Staar Surgical has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Staar Surgical shares have declined approximately 23.3% since the beginning of the year, while the S&P 500 has decreased by 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.59 on revenues of $41.03 million, and for the current fiscal year, it is -$0.81 on revenues of $260.45 million [7] Industry Outlook - The Medical - Dental Supplies industry, to which Staar Surgical belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - The Cooper Companies, another player in the same industry, is expected to report quarterly earnings of $0.93 per share, reflecting a year-over-year change of +9.4%, with revenues anticipated to be $995.5 million, up 5.6% from the previous year [9][10]

Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Align Technology (ALGN) and Straumann Holding AG (SAUHY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive ...

Core Insights - The article compares Labcorp (LH) and Merit Medical (MMSI) to determine which stock offers better value for investors [1] Valuation Metrics - Labcorp has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Merit Medical has a Zacks Rank of 4 (Sell) [3] - Labcorp's forward P/E ratio is 15.44, significantly lower than Merit Medical's forward P/E of 28.18 [5] - Labcorp has a PEG ratio of 1.57, while Merit Medical's PEG ratio is 2.74, suggesting Labcorp is expected to grow earnings at a more favorable rate [5] - Labcorp's P/B ratio is 2.50 compared to Merit Medical's P/B of 3.96, indicating Labcorp is more favorably valued against its book value [6] - Based on these metrics, Labcorp earns a Value grade of A, while Merit Medical receives a Value grade of D [6] Earnings Outlook - Labcorp is noted for its improving earnings outlook, which enhances its attractiveness as a value investment [7]

Henry Schein (HSIC) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $1.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.60%. A quarter ago, it was expected that this health care products maker would post earnings of $1.19 per share when it actually produced earnings of $1.19, delivering no surprise.Over the last four quarters, the co ...

Core Insights - Pro-Dex, Inc. (PDEX) reported quarterly earnings of $0.98 per share, significantly exceeding the Zacks Consensus Estimate of $0.47 per share, and up from $0.19 per share a year ago, representing an earnings surprise of 108.51% [1] - The company posted revenues of $17.41 million for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 1.62%, but up from $14.29 million year-over-year [2] - Pro-Dex shares have increased approximately 40.5% since the beginning of the year, contrasting with a -5.3% decline in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.48 on revenues of $18.5 million, and for the current fiscal year, it is $2.30 on revenues of $67.9 million [7] - The estimate revisions trend for Pro-Dex is mixed, leading to a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Dental Supplies industry, to which Pro-Dex belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Another company in the same industry, Dentsply International (XRAY), is expected to report a year-over-year earnings decline of 31% for the quarter ended March 2025, with revenues anticipated to drop by 10.7% [9][10]